LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...
May 14 (Reuters) - EyePoint said on Thursday an independent safety committee found no new concerns in two late-stage trials of its experimental eye disease drug Duravyu and recommended the studies ...
MedPage Today on MSN
More Evidence that GLP-1s May Reduce Risk of Vision-Robbing Eye Diseases
Significantly lower AMD risk compared with other agents in cohort study ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...
According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...
A new study published in the Journal of the American Medical Association found that administration of anti–vascular ...
Purpose The cross-sectional and longitudinal associations between accelerated biological ageing and the risk of cataract and ...
PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...
Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.
Many common conditions linked to aging develop without symptoms for years. Learn which five pose the biggest risks and the ...
But when the retina is damaged, vision can slowly become blurred, distorted or permanently lost, often before a person even ...
About Dr. James Leong: Dr. James Leong is an Oxford fellowship-trained consultant ophthalmologist specializing in medical retina, uveitis, and refractive cataract surgery. He is the founder of The Eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results